The aggressiveness of early breast cancer and the overall prognosis of patients with the disease is highly dependent on the presence of aberrations in the tumor. HER2 overexpression, in particular, is found in 10% to 40% of breast tumors, which make tumors with these characteristics less responsive to the hormone therapy and cytotoxic agents most commonly used for the treatment of breast cancer.1

Although HER2 positivity has been identified as a predictive factor of response to chemotherapy, it remains controversial considering that responses to chemotherapy can vary in patients with certain disease characteristics. Once trastuzumab (Herceptin), the first targeted therapy for HER2-positive breast cancer entered the paradigm, it was clear that patients had more options,1,2 but, experts were unaware of how far targeted therapies could go in terms of improving outcomes.

Treatment should be individualized based on the patients presenting characteristics, including tumor size, lymph node status, and hormone receptor status, Kari B. Wisinski, MD, medical oncologist, UW Health and the University of Wisconsin Carbone Cancer Center, told Targeted Oncology, in an interview.

Individualizing therapy for our patients with HER2-positive disease can help us improve outcomes and decrease toxicity for our patients, added Sara Tolaney MD, MPH, associate director, Susan F. Smith Center for Women's Cancers, director, Clinical Trials, Breast Oncology, and senior physician, at the Dana-Farber Cancer Institute, and assistant professor of medicine, at Harvard Medical School.

Before the Agent Boom in HER2-Positive Breast Cancer

As a newly introduced targeted therapy in the field of HER2-positive breast cancer in 1998, trastuzumab added to cytotoxic chemotherapy demonstrated a significant improvement in disease-free survival (DFS) in patients with HER2-positive breast cancer, according to results from the N9831 trial (NCT00005970). The result was a 10-year DFS rate of 73.7% with the addition of trastuzumab compared with 62.2% with chemotherapy alone (HR, 0.60; 95% CI, 0.53-0.78) and the 10-year OS rate achieved was 84% versus 75.2% (HR, 0.63; 95% CI, 0.54-0.73).3

As scientific advances were made, trastuzumab continued to be used with chemotherapy, but novel targeted therapies also emerged in the landscape.2

The Thriving Targeted Therapy Research in HER2-Positive Breast Cancer

Many targeted therapies are now FDA approved as treatment of patients with early HER2-positive breast cancer and, unsurprisingly, many of the regimens used in clinical trials for these patients include trastuzumab or are intended to be administered after trastuzumab treatment is completed.

Several new targeted therapies have emerged in the last several years for HER2-positive breast cancer. First of all, we have pertuzumab [Perjeta], the anti-HER2 monoclonal antibody, which has been supported in the neoadjuvant setting as well as in the adjuvant setting. There is neratinib [Nerlynx], which is an oral tyrosine kinase inhibitor that is now approved as an extended duration anti-HER2 treatment following completion of 1 year of trastuzumab in the adjuvant setting, Wisinski explained.Lastly, we have recent data for T-DM1 [trastuzumab emtansine; Kadcyla], which is now FDA approved in the post-neoadjuvant setting in patients with residual disease after standard upfront chemotherapy and anti-HER2 directed therapy. Each of these 3 medications has significantly changed our landscape.

One of the most revolutionary clinical trials exploring the use of novel targeted therapies in patients with breast cancer is the I-SPY-2 platform trial, which includes a subset of patients with HER2-positive disease. I-SPY-2 is a series of mini studies of novel drugs combined with chemotherapy compared with single-agent standard of care, which is the combination of paclitaxel plus trastuzumab followed by doxorubicin and cyclophosphamide. The trial includes 4000 patients.

The combination treatment arms being explored in I-SPY-2 include AMG 386 with or without trastuzumab, AMG 479 (Ganitumab) plus metformin, MK-2206 with or without trastuzumab, T-DM1 plus pertuzumab, pertuzumab plus trastuzumab, talazoparib (Talzenna) plus irinotecan, patritumab plus trastuzumab, durvalumab (Imfinzi) plus olaparib (Lynparza), and cemiplimab (Libtayo) plus durvalumab plus olaparib. The monotherapy arms include ganetespib, ABT-888, neratinib, PLX3397, pembrolizumab (Keytruda), SGN-LIV1A, tucatinib (Tukysa), and cemiplimab, in all breast cancers.4

Aside from the I-SPY-2 trial, vaccine therapies including the HER2-sensitized dendritic

cell vaccine (NCT0338755), the dendritic cell vaccine compared to the WOKVAC vaccine (NCT03384914), and TPIV100, another HER2 vaccine (NCT04197687) are under investigation in phase 1/2 clinical trials.

There have also been studies of combination chemotherapy like trastuzumab plus chemotherapy (NCT03894007), which is a phase 2 study evaluating treatment before surgery in patients with HER2-amplified early breast cancer. Therapeutic strategies that are even further along in the pipeline are immune checkpoint inhibitor monotherapy and immunotherapy and chemotherapy combination that first demonstrated efficacy in other diseases.

The immunotherapy agents and combinations currently under investigation for early HER2-positive breast cancer include the phase 2, open-label, randomized, multicenter trial of paclitaxel plus pembrolizumab versus pembrolizumab alone (NCT03747120); the phase 2 trial of doxorubicin, cyclophosphamide, and paclitaxel plus nivolumab (Opdivo; NCT03742986) in inflammatory breast cancer, which includes patients with HER2-positive disease in 1 arm who will be treated with added trastuzumab and pertuzumab; as well as the single-arm, open-label study of M7824 ahead of standard neoadjuvant therapy (NCT03620201), which is evaluating patients with stage II or III HER2-positive breast cancer.

Expanding the Possibilities of Trastuzumab

Trastuzumab is considered a standard chemotherapy backbone in the landscape of HER2-positive breast cancer.1 To keep the efficacy going, Wiscinski suggests using trastuzumab not only to escalate but also to de-escalate treatment.

One of the strategies that still needs to be considered is not just escalating treatment with these newer agents, but also the idea of deescalating for smaller HER2-positive breast cancer. In particular, I am thinking about either the regimen of paclitaxel with trastuzumab or T-DM1 as a single-agent, Wiscinski stated. Overall, the escalation treatment strategy is sometimes appropriate, but other times, de-escalation is a critical thing for treating HER2-positive breast cancer.

Tolaney also noted, during an interview, that de-escalation plays a critical role in how patients with HER2-positive breast cancer are treated.

By tailoring adjuvant therapy based on response to preoperative therapy, we are able to escalate therapy for patients with residual disease, and de-escalate for patients with pathologic complete response, Tolaney stated.

The de-escalation strategy is an area of active research as well. Currently, the CompassHER2-pCR study (NCT04266249), the PALTAN study (NCT02907918), and the TOUCH trial (NCT03644186) are all investigating de-escalation of trastuzumab-containing regimens.

Wiscinski noted, however, that challenges do exist with this strategy and should be explored future.

An unmet need is having better predictors of who needs an escalation treatment and who can have their treatment de-escalated. For example, right now we rely a lot on nodal status and tumor size, but there could potentially be genomic markers or diagnostic tests that could help us identify which patients have very HER2-sensitive disease and potentially could be treated with less chemotherapy, she explained.

References:

1. Kurebayashi J. Biological and clinical significance of her2 overexpression in Breast Cancer. Breast Cancer. 2001;8(1):45-51. doi:10.1007/BF02967477

2. Sharifi M, Wisinski KB. Advances in the treatment of early-stage her2-positive breast cancer. Clin Adv Hematol Oncol. 2020;18(8):482-492.

3. Perez EA, Romond EH, Suman VJ, et al. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol. 2014;32(33):3744-3752. doi:10.1200/JCO.2014.55.5730

4. The I-SPY 2 Trial. I-SPY2 website. Accessed October 2, 2020. https://bit.ly/36qn2Kk

View post:

Trastuzumab-Containing Regimens and Novel Drugs Mark the Precision Medicine Era of HER2-Positive Breast Cancer - Targeted Oncology

Aimed at offering Global Regenerative Medicine Market: Size and Forecast with Impact Analysis of COVID-19 (2020-2024) report readers with updated information as well as market relevant cues to leverage uninhibited growth in the Global Regenerative Medicine market, this intricately researched, designed, and articulated real-time reference of the market is a culmination of in-depth research mettle and best in class primary and secondary research initiatives that collectively influence a favorable growth trajectory in the Global Regenerative Medicine market.

In continuation with all the above market specific information furnished above, the report further in its subsequent sections also throws light upon other additional yet pertinent details that further channelize revenue generation in the Global Regenerative Medicine market. The report highlights massively the core growth propellants such as market driving factors, prevailing challenges and the like that tend to have a negative growth impact on the global Global Regenerative Medicine market.

Request a sample of Global Regenerative Medicine Market report @ https://www.orbisresearch.com/contacts/request-sample/4707408

Key Manufacturers Analysis:

Novartis AGMedtronic PlcBristol Myers Squibb (Celgene Corporation)Smith+Nephew (Osiris Therapeutics, Inc.)

Global Regenerative Medicine market Segmentation by Type:

Type IType IIType III

Global Regenerative Medicine market Segmentation by Application:

Application IApplication IIApplication III

Access full report @ https://www.orbisresearch.com/reports/index/global-regenerative-medicine-market-size-and-forecast-with-impact-analysis-of-covid-19-2020-2024

Various other dynamics of the Global Regenerative Medicine market pertaining to the growth prospects have been mentioned and well elaborated in the course of the report documentation thus ushering a novel perspective for the players to instrument growth propelling business decisions, defying stringent competition in the Global Regenerative Medicine market. Based on a thorough analytical review leading players comprising both established and new market aspirants in the Global Regenerative Medicine market can have a thorough understanding about the market and subsequently chalk out elaborate plans to steer remunerative returns in the aforementioned Global Regenerative Medicine market.

Key Regions:

North AmericaEuropeAsia PacificROW

All the mentioned updates about the Global Regenerative Medicine market specified in the report have been derived post a dedicated research initiative comprising primary and secondary research practices. Proceeding into unraveling new developments in the report pertaining to the Global Regenerative Medicine market, the report is committed to offer a decisive, problem solving approach based on which readers are encouraged to unravel the various discerning factors and inputs that collectively orchestrate an optimistic growth trail in the discussed Global Regenerative Medicine market.

Ready-to refer Market Insider Reports: Top Reason to Buy the Report

1. A team of expert research veterans, practicing best in industry roles to derive real time developments in the Global Regenerative Medicine market, affecting growth.2. Systematic segment-wise analysis to identify growth reckoning segment.3. A thorough historical study to decode future growth trajectory.4. Rear view analysis of opportunity landscape and barrier analysis and threat identification.5. Astute analysis of the competition spectrum to identify market leaders and their growth favoring business tactics.

Make an enquiry of this report @ https://www.orbisresearch.com/contacts/enquiry-before-buying/4707408

ABOUT US:

Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.

CONTACT US:

Hector CostelloSenior Manager Client Engagements4144N Central Expressway,Suite 600, Dallas,Texas 75204, U.S.A.Phone No.: +1 (972)-362-8199; +91 895 659 5155

The rest is here:

Global Regenerative Medicine Market 2020 Growth Analysis, Trends, COVID-19 Analysis and Forecast to 2024, Key Manufacturers- Novartis AG, Medtronic...

Police departments have been participating in the national Drug Take Back event since 2010 to collect extra and unused prescription medications. (WYDaily file/Courtesy Williamsburg Police Department)

If youre looking to clean out your medicine cabinet, then October is the perfect time to do it.

The York-Poquoson Sheriffs Office, James City County Police and the Williamsburg Police Department are each hosting Drug Take Back events on Oct. 24 from 10 a.m.- 2 p.m.

The event is a Drug Enforcement Administration regulated event.

Too often, unused prescription drugs find their way into the wrong hands. Thats dangerous and often tragic, Shelley Ward, spokeswoman for YPSO, wrote in an email.

Thats why its great to see hundreds of folks from across our area safely and anonymously clean out their medicine cabinets, Ward added.

In a non-COVID year, local law enforcement agencies typically hold events like this twice a year. But Williamsburg Police Officer Aundrea Holiday said the department had to cancel their April Drug Take Back.

Statistics show when you leave the unused medication around, then it gets into the hands it shouldnt be, whether it be teenagers or young kids, Holiday said. We can go ahead and destroy it safely. Its a win-win for the community.

She added flushing prescription medication and other drugs is not an effective nor safe way to dispose of these items because it gets in the waterways.

All locations are accepting prescription solid dosage medications, including tablets and capsules. Intravenous solutions, liquid medications, over-the-counter medications, injectables and needles will not be accepted, nor will illicit substances, including marijuana and methamphetamines. E-cigarettes and vaping devices will only be accepted if the batteries have been removed.

Williamsburg Police collaborated with the Williamsburg Fire Department across the street so they are allowed to accept over the counter medications and sharps, such as needles, at their location.

The James City County Police Department will have their drug take back at the county Law Enforcement Center on 4600 Opportunity Way.

Williamsburg Police is having their event at the Williamsburg Fire Department on 440 N Boundary St. There will be a drop box outside so people can remain in their vehicles when dropping off medication.

The YPSO will have their Drug Take Back at the Department of Public Works on 105 Service Drive. In an effort to keep people safe, deputies will go vehicle to vehicle with a container to collect medications.

YOU MIGHT ALSO WANT TO CHECK OUT THESE STORIES:

Always be informed. Click here to get the latest news and information delivered to your inbox

Go here to read the rest:

Need an excuse to clean out your medicine cabinet? Here it is - WYDaily

Sir, As individuals and members of the Irish Palliative Medicine Consultants Association (IPMCA), we are gravely concerned by any proposal to legislate for assisted suicide and euthanasia in Ireland.

Based on our collective experience over many decades of providing specialist care to thousands of individuals in Ireland and their families each year, we have closely observed the experiences of people who have lived and are living with serious illness.

The threats of the proposed Bill to healthcare in Ireland, to the true meaning of the doctor-patient relationship and to the future of what we know compassionate and supportive specialist palliative care to be are many. We worry about the impact on people who already struggle to have their voices heard in our society older adults, the disabled, those with mental illness and others. We worry that the most vulnerable are those who may be made to feel a burden to their families and come under pressure to end their lives prematurely.

Our experiences tell us that many in our society dont really know what dying is like, or how rare it is that severe pain cannot be controlled. Most people do not see that within the easing of physical, psychological or spiritual distress and addressing peoples fears, hopes, sadness and loss, the goal of palliative care remains to enhance the living of each life which often transforms the experiences of living, dying and bereavement for individual patients and their families.

We are convinced that as dying with dignity is already present within healthcare in Ireland, no change to our current laws is required. Yours, etc,

FEARGAL TWOMEY,

Consultant Physician

in Palliative Medicine,

Limerick and

Chairman of the Irish

Palliative Medicine

Consultants Association;

Prof TONY OBRIEN,

Clinical Professor

of Palliative Medicine,

University College Cork;

Dr MARIE TWOMEY,

Consultant in Palliative

Medicine,

St Lukes Hospital,

Dublin 6;

Dr NORMA OLEARY,

Consultant Physician

in Palliative Medicine,

Our Ladys Hospice

and Care Services and

St Jamess Hospital,

Dublin 8,

Dr VAL OREILLY,

Consultant in Palliative

Medicine,

Limerick;

Prof KAREN RYAN,

UCD Clinical Professor,

Consultant in Palliative

Medicine;

Dr DENISE HAYES,

Consultant in Palliative

Medicine,

University Hospital

Waterford;

FAITH CRANFIELD,

Consultant in Palliative

Medicine,

St Francis Hospice

Blanchardstown and

Connolly Hospital,

Dublin 15;

MARIAN CONROY,

Consultant Physician in Palliative Medicine,

UL Hospitals Group and

Milford Care Centre, Limerick;

Dr MAGS CLIFFORD,

Consultant in Palliative Medicine

Cork Kerry Community Healthcare,

Kerry Specialist

Palliative Care Services,

University Hospital Kerry;

Dr CATHRYN BOGAN,

Consultant in Palliative Medicine

North West Hospice,

Sligo University Hospital;

Dr AISLING OGORMAN,

Consultant Physician

in Palliative Medicine,

Honorary Clinical Senior Lecturer,

Royal College of Surgeons in Ireland,

Louth & Meath Specialist Palliative

Care Services,

Dchas Centre,

Our Lady of Lourdes Hospital,

Drogheda;

Dr CLARE MCALEER,

Consultant in Palliative Medicine ,

Beaumont Hospital,

and St Francis Hospice, Raheny;

Dr BARBARA

SHEEHY-SKEFFINGTON,

Locum Consultant

in Palliative Medicine,

Our Ladys Hospice and Care Services,

and St Jamess Hospital, Dublin;

Dr. BERNADETTE BRADY,

Consultant in Palliative Medicine,

Tallaght University Hospital;

Dr EILEEN MANNION,

Clinical Lecturer

in Palliative Medicine, NUIG,

Consultant in Palliative Medicine,

Galway University Hospital and Roscommon,

Clinical Lecturer in Palliative Medicine, NUIG,

Consultant in Palliative Medicine,

Galway University Hospital

& Portiuncula University Hospitals;

DR MAEVE OREILLY,

Consultant in Palliative Medicine,

St Lukes Hospital, Dublin,

Locum Consultant in Palliative Medicine,

UL Hospitals Group

and Milford Care Centre, Limerick.

See original here:

Palliative medicine and dying with dignity - The Irish Times

CHICKEN soup has been known and loved throughout the world for centuries. a little research shows this dish may have its origins in ancient Greece or perhaps in China (the Chinese being the first to think of adding noodles), but that it is also practically synonymous with traditional Jewish cooking.

Besides being tasty and comforting, chicken soup is also known for the curative properties that have earned it the nickname of Jewish penicillin. And chicken soups health benefits arent just another folktale told to get you to clean your plate (or rather, bowl).

Science Daily says that researchers from the Pulmonary and Critical Care Medicine Section of the Nebraska Medical Center studied how chicken soup interacted with blood samples and found that it did seem to have an anti-inflammatory effect that could possibly work to inhibit respiratory problems.

While researchers couldnt determine exactly what ingredient in the chicken soup was working to reduce inflammation, clinical dietitian Sandy Allonen gives her take on just how chicken soup works its magic.

She calls its clear broth warm and soothing, something that makes it a great source of hydration while youre sick, especially if you have a sore throat. She also notes that even the salt, as well as the other seasonings, can help combat the feeling of dull taste buds, while the veggies have vitamins and minerals that can help build a healthy immune system to fight off viruses and helpyour body recover from illness more quickly.

The carbs in the noodles will help fill you up, satisfy, and re-energize you, while the chicken is not only packed with immune-boosting protein as well as vitamins and minerals of its own but also contains high levels of tryptophan, a substance that Allonen says helps your body produce serotonin that can enhance your mood. Even the steam can help, if you serve your soup piping hot, by opening up airways, making it easier to breathe and producing a mild anti-inflammatory effect that can help relax your muscles and soothe the discomforts of cold symptoms.

Whether you make homemade chicken soup or open up a can, better stock up before cold and flu season hits. It may not be a miracle cure, but chicken soup really is the best medicine.

We hope you enjoyed this article Chicken soup really is the best medicine..

Euro Weekly News is delighted to continue to be able to bring you a range of News that doesnt cost you anything but your internet connection. Whether its Local Spanish News or International Entertainment News, weve got you covered!

View post:

Chicken soup really is the best medicine - Euro Weekly News

PITTSBURGH (KDKA) Major news for COVID-19 patients fighting the virus.

On Wednesday, the University of Pittsburgh School of Medicine said that it is operating one of the 25 nationwide sites that will test therapies aimed at treating early-stage COVID-19 cases.

This trial is part of the National Institutes of Health ACTIV initiative.

Pitt School of Medicine says it aims to develop a treatment that can prevent people with COVID-19 from progressing, which will later require them to go to the hospital.

They say the first drug being studied in the trial is an antibody treatment made by pharmaceutical company Lilly. Researchers say Lillys antibody was shown to help people with COVID-19.

According to the university, phase 2 of the trial is already underway. 110 participants will be recruited nationwide to receive an antibody. Theyll be compared to 110 participants who will receive a placebo. If the medication produces positive results, without significant safety concerns, it will advance to phase 3.

Researchers are looking for people to participate in the study. For more information to see if you qualify, click here.

See original here:

Pitt School Of Medicine Launches COVID-19 Therapy Testing Site - CBS Pittsburgh

The Wayne State University School of Medicine community will examine issues of racism, discrimination and health inequities during Diversity Week, beginning with the Racism in Medicine and Detroit Summit on Oct. 5.

Planned and hosted by members of the schools Learning Communities, the Black Medical Association, and the Institutional Justice and Inclusion External Senate Committee, organizers said they designed the summit and the weeks events to be beneficial for all students with all areas of expertise.

Those organizers include members of the schools Racism in Medicine and Detroit Summit and Diversity Week Task Force, Sara Saymuah, Capricia Bell, Suma Alzouhayli, Manvir Sandhu, Ashleigh Peoples and Ntami Echeng.

While the topics of racism, discrimination and institutional injustices are complex and can be uncomfortable to discuss, the task force members said, these issues and topics influence our patient population and the way we practice medicine. The emphasis on social determinants of health and the influence of racism and discrimination in medicine is a growing topic. Coming from Detroit, a center for urban excellence, comes with a greater expectation of experience with these topics in real time.

The Oct. 5 summit, which begins at 6 p.m.,will introduce the history of racism in the Detroit community, medical education and in medical practice.

Year 1 and Year 2 students can receive a maximum of four clinic service-learning hours by taking part in the weeks events. The Oct. 5 summit will count for two hours for Year 2 students only. To be eligible, students must complete pre- and post-event surveys.

All events are free and are scheduled to take place via Zoom from 6 to 8 p.m. Register for each event separately at the associated links below.

The weeks agenda and topics include:

Oct. 5: Racism in Medicine and Detroit Summit. Medicine can be learned anywhere. Learning how structural racism influences the Detroit community and medical education will provide context for the urban excellence training at the WSU School of Medicine and the unique skills needed to care for an underserved population. Featuring Rhonda Dailey, M.D.; Carmen McIntyre Leon, M.D.; Ijeoma Nnodim Opara, M.D.; and Lewis Graham. You can submit questions for the panelists here.

Oct. 6: Racism as a Form of Trauma,6 to 7:30 p.m., featuring Carmen McIntyre Leon, M.D., followed by a dialogue circle facilitated by the Office of Diversity and Inclusion from 7:30 to 8:30 p.m. If you can begin to understand how racism in all forms has negative effects on individual and community health you can begin to understand how to combat this for yourself and for the people and patients you care for. The impact of racism is complex, but learning how to define and categorize responses to various forms of racism will help you piece together how you can make positive impacts moving forward. This event is co-sponsored by the Latino Medical Student Association.

Oct. 7: Our Identities and Intersectionality, 6 to 7 p.m., featuring Arash Javanbakht, M.D.How does your identity benefit or hinder your performance in certain spaces? Do you feel confident in some but shy in others? Why is that? What factors are at play? Attend to learn more about the importance of understanding your identity. Co-sponsored by the Islamic Medical Student Association and the National Arab American Medical Association NextGen. This will be followed by Smores and Wards, Medical Education and Discrimination, 7 to 8 p.m. What really happens on rotations? The sharing of stories can provide benefit in learning but also in building a supportive community around injustices experienced by your fellow medical students. What would you do if you encountered this? What will/would you do if you see this done to a fellow classmate?

Oct. 8: Healthcare and Vulnerable Communities, 6 to 7 p.m., featuring Ijeoma Nnodim Opara, M.D. Racism embedded in the structure of our society and institutions deters many from beginning to understand how we got here and why. However, the future of medicine and the future of our communities that we entered this profession to care for depends on it. By attending this session you will learn about the structural influences of health disparities and more importantly how to combat them. Co-sponsored by the American Medical Womens Association and the Cass Clinic. Followed by COVID-19: Racism and Health Inequity Zoom-talk, 7 to 8 p.m. Youve probably learned about the health disparities that the COVID pandemic blatantly exacerbated. But did you get a chance to talk about what this means for the Detroit community, current or future health advocacy efforts, or for you as a future physician? Join the discussion, learn the opinions of other students and share your insight. There is a need for transparency and collaboration amongst students, faculty and practicing physicians, and this could be where it starts.

Oct. 9: Allyship for Our Peers and Patients, 6 to 7 p.m., featuring Kevin Wang, M.D. Regardless of race, gender, sexual orientation - there is a place for you in social justice advocacy in the medical field. Everyone is welcome, and more importantly everyone is needed. This event can help you understand what it means to be an ally and how to use your powers effectively. Co-sponsored by LGBT+ People in Medicine. Followed by How to Be a Better Ally, 7 to 8 p.m., featuring Latonya Riddle-Jones, M.D.; Diane Levine, M.D.; Elizabeth Secord, M.D.; the Corktown Health Centers Patrick Yankee; the Callen-Lorde Community Health Centers Andrew Goodman, M.D.; and Henry Fords Ruth Ellis Center. Now that youve learned about racism, identity, advocacy and allyship, this is your opportunity to put them all together. By attending this panel you will hear how experts have pieced together these complex concepts and how they use them to make a positive impact. The discussion will be guided based on personal experiences and episode 10 from the podcast The Happiness Lab: How to Be a Better Ally.

Read more from the original source:

Diversity Week kicks off with Racism in Medicine and Detroit Summit on Oct. 5. - The South End

CAMBRIDGE, Mass., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that management will participate in the following upcoming investor conference:

Chardan Virtual 4th Annual Genetic Medicines ConferenceFireside ChatDate: Monday, October 5, 2020Time: 10:30 a.m. ET

The event will be webcast live and may be accessed on the Editas Medicine website in the Investors and Media section. Archived recordings will be available for approximately 30 days following the event.

About Editas MedicineAs a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a (also known as Cpf1) genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. For the latest information and scientific presentations, please visit http://www.editasmedicine.com.

Investor ContactMark Mullikin(617) 401-9083mark.mullikin@editasmed.com

Media ContactCristi Barnett(617) 401-0113cristi.barnett@editasmed.com

Original post:

Editas Medicine to Participate in Upcoming Investor Conference - GlobeNewswire

Michigan Medicine is participating in a nationwide study funded by the National Institutes of Health that will seek to discover the cause of several unusual forms of diabetes. For years, doctors and researchers have been stymied by cases of diabetes that differ from known types. Through research efforts at Michigan Medicine and 19 other U.S. research institutions, the study aims to discover new forms of diabetes, understand what makes them different, and identify their causes.

The Rare and Atypical Diabetes Network, or RADIANT, plans to screen about 2,000 people with unknown or atypical forms of diabetes that do not fit the common features of type 1 and type 2 diabetes.

A person with atypical diabetes may be diagnosed and treated for type 1 or type 2 diabetes, but not have a history or signs consistent with their diagnosis. For example, they may be diagnosed and treated for type 2 diabetes but may not have any of the typical risk factors for this diagnosis, such as being overweight, having a family history of diabetes, or being diagnosed as an adult. Alternately, a person with atypical diabetes may respond differently than expected to the standard diabetes treatments.

Were excited to contribute to the RADIANT study through our deep commitment to understand and better treat rare and unusual forms of diabetes, says Elif Oral, M.D., an endocrinologist at Michigan Medicine. Michigan Medicinehas pioneered this field throughthe work of Dr. Stefan Fajan by defining Maturity-Onset Diabetes of the Young and we carried the torch in our current division through the work of Dr. Peter Arvans lab and our clinical translational studies in lipodystrophy.

RADIANT researchers will build a comprehensive resource of genetic, clinical, and descriptive data on previously unidentified forms of diabetes for the scientific and healthcare communities.

The studys researchers will collect detailed health information using questionnaires, physical exams, genetic sequencing, blood samples, and other tests. People found to have unknown forms of diabetes may receive additional testing. Some participant family members may also be invited to take part in the study.

We are thrilled that Dr. Orals team at the University of Michigan Elizabeth Weiser Caswell Diabetes Institute has been chosen for this important study, says Martin G. Myers, Jr., M.D., Ph.D., director of the Institute. In addition to helping to understand the causes of diabetes, Dr. Orals work has the potential to identify new and better treatments for patients in the RADIANT study and for others with diabetes.

USF is the studys coordinating center, and the lead centers include Baylor College of Medicine in Houston and the University of Chicago. The Broad Institute in Cambridge, Massachusetts, and Baylor serve as the genomic sequencing centers for the project. University of Florida, Gainesville, provides the studys laboratory services. Other participating centers are:

Support for the study is provided through NIDDK grants U54DK118638 and U54DK118612.

Excerpt from:

Michigan Medicine participates in first nationwide network to study rare forms of diabetes - University of Michigan Health System News

Friday, October 2, 2020

The Purdue University College of Veterinary Medicine is being honored today as a recipient of the 2020 Health Professions Higher Education Excellence in Diversity (HEED) Award from INSIGHT Into Diversity magazine, the oldest and largest diversity-focused publication in higher education. Presented annually, the national Health Professions HEED Award recognizes U.S. colleges and universities that demonstrate an outstanding commitment to diversity and inclusion. Insight Into Diversity magazine made the announcement today (Friday, October 2). As an award recipient, the college will be featured, along with 45 other recipients, in the December 2020 issue of the magazine.

Dean Willie Reed said the award is a great reflection of the colleges deep and abiding commitment to diversity, equity, and inclusion. This award makes an important statement about the way in which our college doesnt just talk about diversity and inclusion, but lives it, Dean Reed said. The Purdue University College of Veterinary Medicine is playing a leadership role nationally with model initiatives that advance diversity and inclusion in veterinary medicine.We are working diligently to make measurable progress as a college and as a profession in being truly welcoming and supportive of everyone and this award documents that fact.

This is the second year Purdue Veterinary Medicine has been named as a Health Professions HEED Award recipient. PVM continues to raise the bar in diversity, equity, and inclusion through its innovative programming and leadership, said Dr. Latonia Craig, the colleges assistant dean for inclusive excellence. We are so thrilled for PVM to receive this award. Diversity, Equity, and Inclusion lie at the heart of PVMs mission. We have a supportive college community that makes every effort to ensure we bring our core values to life daily. This work is not easy, but we do it because thats just who we are, Dr. Craig explained. You can have diversity without inclusion, but at PVM, we strive to create an environment that welcomes and includes each student, faculty, and staff member. We hope that our efforts will inspire others to engage in this work in the best way they know how.

INSIGHT Into Diversity magazine selected Purdue Veterinary Medicine for the award because of its multiple diversity and inclusion initiatives. In February, the college launched its five-year diversity strategic plan, which continues to receive praise for its thoroughness and commitment to inclusive excellence. PVMs role in advancing diversity, equity, and inclusion in veterinary medicine is long-standing. Award-winning programs such as Vet Up!, led by Dr. Craig, and This is How We Role, led by Dr. Sandra San Miguel, associate dean for engagement, each received INSIGHT Into Diversity magazines Inspiring Programs in STEM Award in 2019 and 2020, respectively. Other programs include PVMs new and popular virtual Learning Cafs, a monthly series of 50-minute critical conversations surrounding diverse topics chosen by the PVM community.

The HEED Award process consists of a comprehensive and rigorous application that includes questions relating to the recruitment and retention of students and employees and best practices for both, continued leadership support for diversity, and other aspects of campus diversity and inclusion, said Lenore Pearlstein, publisher of INSIGHT Into Diversity magazine. We take a detailed approach to reviewing each application in deciding who will be named a HEED Award recipient. Our standards are high, and we look for institutions where diversity and inclusion are woven into the work being done every day across their campus.

The other recipients of the 2020 Health Professions HEED Award include three other veterinary schools:

Click here for more information about the 2020 Health Professions HEED Award.

Writer(s): Kevin Doerr | pvmnews@purdue.edu

Visit link:

Purdue Veterinary Medicine Receives 2020 Health Professions Higher Education Excellence in Diversity (HEED) Award - Purdue Veterinary News

Figure:

fellowships

When emergency medicine was still the new kid on the block in the 1990s, fellowship opportunities for graduates were few and far between, and the only options were EMS, pediatric emergency medicine, and toxicology. This made each graduate's choice a little easier in many ways. You could take a clinical job and make as much money as you could ($100 per hour was good money then), or you could take an academic position that paid considerably less (around $120,000 a year).

Funny what a few decades will do. Literally hundreds of fellowship positions are available to EM graduates these days with many optionsacademics, research, sports medicine, critical care, simulation medicine, global health, population health, palliative care, telemedicine, and clinical ultrasound. The Accreditation Council for Graduate Medical Education 2020 match results demonstrate that a substantial percentage of the three most popular EM fellowship programs went unfilled. (See table.)

These data come from the 2020 National Residency Matching Program (NRMP) report for fellowships, and this sample of fellowships in emergency medicine, pediatrics, internal medicine, and surgery shows that almost half of the available positions for the three most common EM fellowships did not fill. Clinical ultrasound trailed all of them by filling only 45 percent of programs. On the bright side, this created a buyer's market for pending EM grads, and 92 percent of the applicants to these fellowships matched.

Perhaps even more interesting were the number of new clinical ultrasound and EMS positions available this year22 for clinical ultrasound, even though fewer than half of those positions filled in 2019. EMS was the same: Seventy-six percent of the available positions filled in 2019, and 10 positions were added in 2020, but the match rate fell to 62 percent. At least toxicology moved in the right direction by decreasing from 54 to 51 available positions in 2020, and the percentage of positions that filled went from 67 to 76 percent.

All of this is ironic given the popularity of emergency medicine residency training. Matching into an EM program is relatively competitive compared with other specialties that require three years of post-graduate training. Emergency medicine filled nearly all of its positions for the past 20 years, and 2020 was no different.

I have not mentioned pediatric emergency medicine as a common fellowship for EM graduates because the majority of these positions fill with graduates of pediatrics residencies. Some unpublished reports claim they outnumber EM grads by as many as 20 to 1. (ALiEM. Feb. 20, 2015; https://bit.ly/3aKjbrO.)

Pediatric EM programs are balancing the positions to applicantsall 191 positions matched in 2019, and 99 percent filled in 2020, with only two new positions added. Looking at matches since 2016, 98 percent of pediatric emergency medicine positions filled, but only 77 percent of applicants matched.

What should we make of all of this? First, look at the sample of fellowships in the table for internal medicine and surgery. These fellowships have been around for decades. They have few unfilled programs, and at least 97 percent of the programs filled (except for thoracic surgery at 90 percent). The 2020 NRMP fellowship report lists 66 different types of fellowship training, and 47 of these (71%) filled at least 75 percent of the available positions. Thirty-four (52%) filled at least 85 percent.

To be sure, money drives a lot of these findings. Cardiology and gastroenterology fellowships generate considerably higher incomes compared with the income from just residency training in internal medicine. By contrast, EM fellowships typically do not provide higher levels of income compared with EM residency training alone. This discourages potential EM fellowship applicants from giving up one or two years of high compensation with no future financial reward.

The other interesting finding in the sample of non-EM programs in the table is that 63 to 77 percent of applicants matched. The exception is pediatric surgery, with only 55 percent of applicants matching.

It is evident that emergency medicine puts little thought into when and what to offer as additional post-graduate training through a fellowship. Academic centers are still creating programs in specialties with saturated markets and little chance of routinely filling. This wastes the efforts of academic faculty to perform meaningful work. The amount of time to build and maintain a post-graduate program is considerable. Yet once a fellowship graduate moves to another academic center, he begins work on developing a new program.

This has been particularly true with clinical ultrasound. At the turn of the millennium, there was only one program; now there are 129. That's an average of more than six new programs every year for 20 years. There are only 11 fellowship specialties listed in the NRMP report with more programs. None comes anywhere close to having as many unfilled positions as clinical ultrasound.

The academic centers for emergency medicine need to think strategically about building fellowship programs in tune with demand. There is an expanding number of niche interests in our specialty, and opportunities are available to exploit the low supply of experts in these areas. The current supply and demand for many EM fellowships can produce a dangerous situation in which program directors searching for someone to fill their program select an unqualified applicant. This could create problems in the emergency department when caring for complex patients with residents.

It may be a better time than ever for pending EM graduates to consider fellowship training. It's easy to embrace the idea of making as much money as you can. The explosion of new EM residency programs combined with a skyrocketing number of advanced practice providers, however, means having a niche skill may be the difference between getting and holding on to a great job versus having your hours cut or being forced out.

Dr. Cookis the program director of the emergency medicine residency at Prisma Health in Columbia, SC. He is also the founder of 3rd Rock Ultrasound (http://emergencyultrasound.com). Friend him atwww.facebook.com/3rdRockUltrasound, follow him on Twitter@3rdRockUS, and read his past columns athttp://bit.ly/EMN-Match.

Go here to read the rest:

After the Match: The Emergency Medicine Fellowship Glut : Emergency Medicine News - LWW Journals

Multiple sources have all said the same thing: Donald Trump has no sense of humour. Which is fitting, considering his Presidency was motivated by a punchline.

Clive James claimed that if you didnt have a sense of humour you couldnt be trusted with anything not even to post a letter. His friend, the writer Martin Amis, thought it was closely allied to common sense; in fact, he called humour, common sense dancing. What does this say about the current lay of the land here in America where we are suffering through some of the least funny days in living memory? Nothing good. Poor Clives barely in his grave and already hes being asked to start spinning.

If there is a common revelation in the current avalanche of tell-all Trump books it is this: the president has no sense of humour. He rarely laughs at a joke. He rarely tells a joke. Its impossible to imagine him, head thrown back, tearful and helpless in the face of a funny story or a well-executed gibe. Any humour he does possess is only deployed to make nasty fun of someone. To a book, they all mention this singular lack in the Commander-in-Chief; and here we all thought it was empathy.

Theres a good case to be made that, except for the famously sober-sided George Washington, Americas best presidents have been the funny ones. Lincoln was so fond of a funny story that his Cabinet feared he wasnt serious enough to handle the Civil War. As Jesus used parables so Lincoln used jokes (and this way, way before Freud). FDR loved laughing so much he could barely keep a straight face even through the most serious of speeches. JFK was the first to turn the presidential press briefings into a near stand up routine; everyone looked forward to them. Reagan seemed to always be in on some private joke. How else could a man grin that much? And, Obama can be reasonably held to account for the current president by hilariously taking the piss out of Trump during the 2011 White House Correspondents Dinner. In the middle of that event, with the room convulsed, some even stuffing napkins into their mouths, there sat Trump, immobile, scowling, un-amused, a real stiff and a bad sport. Trump himself says that thats when he decided to run. He wanted to wipe the smile off everyones face; hed teach this black man and this laughing room of press and politicians whats what.

This origin story is a good one to keep in mind when many of Trumps apologists cover for his more extravagant and flagrant howlers by claiming, he was just joking. Really? Ingest bleach as a cure for the coronavirus? Ha, ha, ha cant you take a joke? The virus will just go away, like a miracle? The presidents just pulling your leg; ha ha ha. It is literally the last exit ramp taken by his enablers when confronted with obvious head slappers. The message is: Trumps got this great sense of humour, its just so subtle and deep none of you boneheads can get it.

So, lets do what should never be done on pain of having to spend a nice quiet, social evening with, say, Josef Stalin. Lets consider what practical gain is to be gotten by a sense of humour and why it might be a good trait to have in a leader. For the most part, to recognise and enjoy humour is to be able to run along at least two tracks of meaning at the same time. The shock of a laugh is when one of those meanings breaks into a context you didnt expect. The lowest form, a pun say, is worth a groan because you recognize the original now seen in a different way. The highest form (debatable) is irony, where this double nature is, funnily enough, the whole point.

Thus, a good sense of humour in a leader is an indication that he/she has a nimble, layered mind capable of holding multiple levels of meaning; capable of seeing from many, sometimes conflicting perspectives; can project the present into different contexts, different futures. For the complex issues of governing its nice to know that the one at the top can do more than dance following the numbers on the floor.

Now that we know that drink bleach, lock her up, Id like to punch him in the face Russia, if youre listening are not punch lines this election becomes more and more like being in a comedy club on bomb night. Its embarrassing, uncomfortable, a bit angering and starts you wondering what Stalins up to hes gotta be worth a few laughs.

Link:

Laughter is the best medicine: Donald's immunity to humour - The Big Smoke Australia

BY SANDRA GUY

If youre rusty on your history of natural medicine, its time for a primer and this one just might be a remedy for our continued coronavirus vigilance.

The topic is Ayurveda, one of the oldest healing sciences it originated in India more than 5,000 years ago that translates into The Science of Life in Sanskrit.

Ayurveda posits that everyone comprises three kinds of energy. They go by the Sanskrit terms vata, pitta and kapha.

Vata governs movement, but can be as subtle as breathing, blinking, the heart pulsing and cell membranes regulating materials transport. In terms of balance and imbalance, vata can promote creativity and flexibility or fear and anxiety.

Pitta controls digestion, nutrition, metabolism and body temperature. Its optimal energies boost understanding and intelligence, while its out-of-sync version is said to arouse anger and jealousy.

Kapha provides the glue that holds cells together and provides the energy for bones, muscles and tendons. Its high road expresses as love, calmness and forgiveness, while its evil twin leads to envy, greed and attachment.

These three energies are known as doshas.

Each energy is believed to be positively impacted by three tropical fruits that make up the compound Triphala. The three fruits native to India are believed to promote the health of the doshas.

Though Triphalas effects are scientifically unproven on people, its adherents boost its antioxidant properties. Ayruvedic practitioners tout it for oral health, to boost the immune system and to treat tiredness and upset stomach.

Triphala is available as a pill, a powder, a supplement and a liquid extract.

Experts advise talking to a doctor before taking Triphala.

If you get the go-ahead, Tiphala could well join your nighttime or daytime rituals for staying calm, balanced and creative just when you need it most.

See the original post:

The Science of Life: The Concepts of Ayurvedic Medicine Amid COVID19 - ChicagoNow

Human expression is different from other more biological responses like sweating when were nervous, which is a primal response of the fight or flight kind.

Probably the most common shared experience with the fight or flight response is public speaking the thing that a majority of people fear more than actual death.

What I learned in five years of teaching public speaking and a lifetime of hating it is that the thinking/feeling part of your brain says, No. No. No, no, no! Not a speech! so the primal part of your brain responds, by immediately pumping adrenaline into your body to help you run away, far, far away from the lectern. Or, I guess, fight your way through the crowd to kick open the door so you can run far, far away.

You need fast-twitch muscle action to speed your getaway, or make your assault faster than your opponents. You need more oxygen to feed this work. You need sweat to cool you down from the exertion. Your loud and or piercingly high voice is suited to calling your comrades to your side. The queasy stomach? Adrenalin says a heavy stomach slows you down, so dump the food and divert the stomachs blood supply to more important organs like your heart and lungs.

Weirdly, a small percentage of people will just shut down in face of threats, real or imagined. I had read about it: people speaking in front of an audience whose voices get lower and slower, their movement sluggish. They yawn. Yawn, like theyre falling asleep or something. Who does that?

Being in the sweat-shower and facial tick majority, I thought this was a bunch of hogwash, but then I saw it happen in real life. I think of this response to adrenaline as the play-dead defense. It doesnt get you out of public speaking class any more than getting the yips does, but, undeniably, sometimes it can save your life out in the wild.

Saving your life, nothing is more primal than that, but human expression, thats a little bit loftier stuff.

Language, of course, is not universal. Some gestures cross cultures, but not all of them. We raise a middle finger, someone else raises their fist and slaps their bicep, and another person crosses their fingers but it doesnt mean good luck, at all.

Some physical expressions are universal, though. Through facial expressions we can understand a small set of emotions, generally broken into happiness, sadness, surprise, anger, disgust and fear. By the way, this does help explain the core set of emojis.

Lots of research looks into the universal nature of body postures, such as raising your arms over your head in response to a victory or success, but dropping your shoulders and head down is defeat.

Vocalizations had mixed success. Voice tones are generally understood, but cultural and language barriers can confuse the message. For example, if a person who speaks a melodic language like French hears yelling in a harsher sounding language like Kurdish, it sounds angry even if the yeller is happy because their team won the play-offs.

Interestingly, none of the research I read this week called crying a universally understood expression. Crying occurs for too many different reasons: sorrow, fear, anger, even happiness. Apparently without the visual backup of the persons body or facial language, listeners couldnt consistently speculate on why a person was crying.

The single universally understood vocalization? Laughter.

Laughter is so well understood around the world and our bodies reaction to laughing and even hearing laughter a release of happy little endorphin hormones into the body is so universal, laughter almost qualifies as a primal instinct. A life-saving response, if you will.

To celebrate laughter and its life-saving properties in this stressful time, I will tell you my favorite knock-knock joke. You know how this joke exchange goes: Knock, knock. Whos there? etc., so you have to imagine me saying my part.

For my favorite knock-knock joke to work, you have to start it.

Whos there? Yeah, riddle me that one. Im always disappointed when I have to explain a joke, except with this one. Makes me laugh every time, so Ill walk you through it at [emailprotected] or http://www.facebook.com/viewfromthenorth40 .

Here is the original post:

View from the North 40: It really is the best medicine - The Havre Daily News

WHAT:

Rangeley Family Medicine will be distributing 75 pre-packaged boxes of fresh produce to individuals in the greater Rangeley area.

To protect the health of our patients, we will observe state guidelines associated with COVID-19. Social distancing measures will be required, as well as the use of facial coverings.

WHO:

Anyone in need of emergency food assistance in Rangeley and the surrounding areas is welcome to attend.

WHEN:

Wednesday,September 23rdfrom 10:00 a.m. to 4:00 p.m.

WHERE:

Rangeley Family Medicine, 42 Dallas Hill Road, Rangeley

WHY:

Good Shepherd Food Bank allows us to expand our outreach to Maine communities most affected by food insecurity. Designed to be low-barrier distributions, Good Shepherd Food Bank delivers to communities with a demand for emergency and supplemental food that has outgrown the capacity of local food pantries.

For more information, please contact Rangeley Family Medicine at (207) 864-3303.

______________________________________________________________________________

About Good Shepherd Food Bank

As the largest hunger relief program in Maine, Good Shepherd Food Bank provides for Mainers facing hunger by distributing nutritious foods to more than 400 partner agencies across the state, including food pantries, meal sites, schools and senior programs. Together with its network, the food bank leads a statewide effort to combat the root causes of hunger by engaging in advocacy, nutrition education and strategic partnerships. In 2019, the food bank distributed 25 million meals to families, children and seniors in need throughout Maine.

Website:www.feedingmaine.org

Phone: (207) 782-3554

Facebook:www.facebook.com/feedingmaine

Twitter:www.twitter.com/feedingmaine

Rangeley Family Medicineis part of HealthReach Community Health Centers, a group of 11 Federally Qualified Health Centers in Central and Western Maine. Rangeley offers a wide range of services, including medical care, counseling and care management to residents of Rangeley, Dallas and Lincoln Plantations, Madrid, Magalloway, Sandy River and surrounding towns. A reduced fee program is available to uninsured and underinsured residents.

Previous

Next

Excerpt from:

Food Distribution to take place at Rangeley Family Medicine - The Bethel Citizen

BLOOMINGTON, Ind. (WISH) IU School of Medicine researchers have received a multi-million dollar grant to study a potential treatment for opioid addiction.

Its a five-year project thats expected to cost more than $12 million.

The drug is called tezumpanel and it was actually developed by Eli Lilly and Company and studied for use with migraines more than 10 years ago.

Now, IU School of Medicine researchers along with drug developer Proniras want to see if it can be used effectively to help those going through opioid withdrawal and other addictions as well as mental illnesses.

The medication will first be tested in a preclinical setting. That phase of the study is expected to cost about $2 million and last two years. If that supports further development, the grant will also provide about $10 million for a human clinical trial of the drug in individuals with opioid addiction in Indiana and across the country. That would take about three years. The money is coming from the National Institute on Drug Abuse.

We have a profound need for new and effective treatment for addiction and co-morbid psychiatric conditions. We believe this grant represents an exciting opportunity to move the field of addiction psychiatry treatment forward in an impactful way, Dr. Thomas McAllister, chair of the IU School of Medicine Department of Psychiatry, said.

Proniras licensed exclusive global rights to tezampanel from Eli Lilly and Company in 2017. Since then, the company also tested it as a potential treatment for nerve agent-induced seizures.

Tezampanel is not currently approved for any treatment through the FDA.

More here:

IU School of Medicine study to look at potential treatment for opioid addiction - WISHTV.com

Dublin, Sept. 18, 2020 (GLOBE NEWSWIRE) -- The "National eHealth Initiatives Advancing Global Precision Medicine Market, 2018-2025" report has been added to ResearchAndMarkets.com's offering.

This research service analyzes the key building blocks for the precision medicine ecosystem to provide strategic imperatives and growth opportunities for key participants.

Key Issues Addressed

The study captures both the global and regional flavors for PM market opportunity realization such as: market projections, drivers and restraints, country readiness index, and major government and commercial initiatives. The study also provides live case studies and innovative business models for leading companies in the PM space.

Precision medicine is transitioning toward wider acceptance, due to mounting payer pressures and regulatory changes that are shifting pharma businesses from prescriptive to more predictive and personalized models. Emergence of value-based reimbursement models and healthcare consumerism trends are helping move the treatment model from one-size-fits-all' to a stratified and outcome-based targeted therapeutics concept called precision medicine' (PM).

Companion diagnostics (CDx) and targeted therapeutics (TRx) are going beyond oncology and spreading more toward therapeutic areas such as infectious diseases, central nervous system (CNS), and cardiovascular diseases. Despite a relatively high success rate for PM R&D assets commercialization in recent years, considerable challenges exist around proving clinical utility and a regulatory and reimbursement framework, which is rigid, decentralized, and non-uniform.

Advances in omics technologies help in identifying molecular targets with the help of molecular insights generated by datasets about the disease pathogenesis. PM informatics is the key component of the PM ecosystem. PM-cognitive analytic platforms capable of leveraging genomic, clinical, financial, and lifestyle data, while delivering actionable clinical insights at the point of care, are gaining market traction. Big Data and Artificial Intelligence (AI) are the key enablers for utilizing the full potential of PM for building predictive models based on multi-omics data, given a big hurdle in the adoption of PM is lack of technology infrastructure.

Genomic sequencing has huge potential to support the COVID-19 outbreak exploration, especially in comprehending the re-emergence of potential COVID-19 outbreaks.

In terms of geographic outlook, although the specific focus on PM research started in the United States and the EU, countries such as Canada, China, Australia, Taiwan, South Korea, Singapore, and Japan have made significant advances in recent years in this area by way of significant investments to develop in-country research and scientific expertise to improve access. Considering the infrastructure requirements for utilizing omics in clinical practice, China and Japan are beating other leading countries in terms of both research initiatives and regulations and infrastructure development.

Key Topics:

Executive SummaryKey Questions This Study Will Answer6 Big Themes for Precision MedicinePrecision Medicine - Regional Market OverviewPrecision Medicine Vendor Landscape by Major Market ClustersPrecision Medicine Readiness of Major CountriesKey InsightsPrecision Medicine in the Wake of COVID-19

Research Scope, Definitions, and SegmentationResearch ScopePersonalized Vs Precision MedicinePrecision Medicine CategoriesPatient Stratification - Data Volume, Sources, and AdoptionPrecision Medicine - Key Segments and Data Sources

Current and Future State of Precision MedicineGlobal Precision Medicine Market - Macro to Micro VisioningChanging Modalities of Innovative DrugsPrecision Medicine in the Late-stage Clinical Trials PipelineMajor Pharmacogenomics BiomarkersPrecision Medicine Vendor Landscape

Precision Medicine Market Projections (2019–2025)Scenario Contingent Projections for Core Precision Medicine SegmentForecast Assumptions for Core Precision Medicine Segment - Optimistic ScenarioForecast Assumptions for Core Precision Medicine Segment - Pessimistic ScenarioCore Precision Medicine Segment - Revenue Forecast Scenario AnalysisCore Precision Medicine Segment - Revenue Forecast by SubsegmentsForecast Assumptions - Core Precision Medicine Key Subsegments

Precision Medicine Cluster Benchmarking by Major CountriesSelect Countries’ Readiness for Precision MedicineFactors Consideration for Precision Medicine Country Readiness IndexCountry Readiness for Precision Medicine - USCountry Readiness for Precision Medicine - EU and UKCountry Readiness for Precision Medicine - APAC

Growth Opportunities in Precision MedicineMajor Growth Opportunities

Opportunity Analysis - CDx and Biomarker-based Targeted Therapeutics (TRx)Growth Opportunity 1 - CDx and Biomarkers-based TRxPrecision Medicine Clinical Trials Trends in Major RegionsTop Areas of Companion Biomarker ResearchNew Clinical Trial Designs in the Era of Precision MedicineSelect Countries’ TRx and CDx Readiness Index

Opportunity Analysis - Genomics Technologies for Precision DiagnosticsGrowth Opportunity 2 - Genomics Technologies for Precision DiagnosticsPrecision Medicine Patient Stratification by Omics/Diagnostic FactorsLevel of Adoption of Select Novel Technologies and ApproachesGenomics Technologies for Precision DiagnosticsSelect NGS Vendor LandscapeSelect Countries’ Omics Research Readiness Index

Opportunity Analysis - Precision Medicine InformaticsGrowth Opportunity 3 - Precision Medicine Informatics SolutionsPrecision Medicine Informatics Market LandscapePrecision Medicine Informatics Market SizeC2A: Xifin - Precision Medicine Informatics for MDxSelect Countries’ eHealth Readiness Index

Key Conclusions

Appendix

For more information about this report visit https://www.researchandmarkets.com/r/lvkzh

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Read more from the original source:

Global Precision Medicine Research Report 2020: Taiwan, Estonia, and Finland Emerging as Key Markets Fueling Growth Opportunities in Precision...

Aesthetic Medicine Market Research Report by Type (Invasive Procedures and Non-invasive Procedures), by Gender (Female and Male), by End Use - Global Forecast to 2025 - Cumulative Impact of COVID-19

New York, Sept. 18, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Aesthetic Medicine Market Research Report by Type, by Gender, by End Use - Global Forecast to 2025 - Cumulative Impact of COVID-19" - https://www.reportlinker.com/p05953101/?utm_source=GNW

The Global Aesthetic Medicine Market is expected to grow from USD 9,485.16 Million in 2019 to USD 18,123.69 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 11.39%.

Market Segmentation & Coverage:This research report categorizes the Aesthetic Medicine to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Type, the Aesthetic Medicine Market studied across Invasive Procedures and Non-invasive Procedures. The Invasive Procedures further studied across Breast augmentation, Eyelid Surgery, Liposuction, Nose reshaping, and Tummy tuck. The Non-invasive Procedures further studied across Botox injections, Chemical peel, Laser hair removal, Microdermabrasion, and Soft tissue fillers.

Based on Gender, the Aesthetic Medicine Market studied across Female and Male.

Based on End Use, the Aesthetic Medicine Market studied across Ambulatory Surgical Center, Beauty Center & Medical Spa, Dermatology Clinic, Home Setting, and Hospital.

Based on Geography, the Aesthetic Medicine Market studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region surveyed across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region surveyed across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region surveyed across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Company Usability Profiles:The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Aesthetic Medicine Market including Allergan, Inc, Alma Lasers, Anika Therapeutics, Inc., Cutera, Inc., Cynosure, El.En. S.p.A., Fotona D.O.O, Galderma S.A., Johnson & Johnson., Lumenis, Mentor Worldwide LLC, Merz Aesthetic, PhotoMedex, Solta Medical, Syneron Candela, Valeant International, and Zeltiq Aesthetic.

FPNV Positioning Matrix:The FPNV Positioning Matrix evaluates and categorizes the vendors in the Aesthetic Medicine Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Competitive Strategic Window:The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.

Cumulative Impact of COVID-19:COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlaying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecast, considering the COVID-19 impact on the market.

The report provides insights on the following pointers:1. Market Penetration: Provides comprehensive information on the market offered by the key players2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developments

The report answers questions such as:1. What is the market size and forecast of the Global Aesthetic Medicine Market?2. What are the inhibiting factors and impact of COVID-19 shaping the Global Aesthetic Medicine Market during the forecast period?3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Aesthetic Medicine Market?4. What is the competitive strategic window for opportunities in the Global Aesthetic Medicine Market?5. What are the technology trends and regulatory frameworks in the Global Aesthetic Medicine Market?6. What are the modes and strategic moves considered suitable for entering the Global Aesthetic Medicine Market?Read the full report: https://www.reportlinker.com/p05953101/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Story continues

Go here to see the original:

Aesthetic Medicine Market Research Report by Type, by Gender, by End Use - Global Forecast to 2025 - Cumulative Impact of COVID-19 - Yahoo Finance

The TCU and UNTHSC School of Medicine received a $25 million donation, contributing to the Lead On campaign.

Chancellor Victor Boschini announced the donation from Anne Marion, who died in February, and the Burnett Foundation on Tuesday in an email to students and faculty.

Instituted as The Anne W. Marion Endowment, the donation will be used to help the school become a top provider of medical education, equipping its students with the skills they need to handle complex health care issues, including those involved with serving patients during the COVID-19 pandemic.

The endowment will enhance the School of Medicines communication-based curriculum designed to cultivate empathetic scholars.

Marions Fort Worth family has been a contributor to TCU for over a century, and individually, she was known as a philanthropic leader and a supporter of the universitys advancement.

I am inspired by the vision of the School of Medicine to transform medical education, Marion said before she died. This school is bringing considerable advances and innovations that are reshaping curriculum and preparing its graduates to better serve the community. I am pleased to make this gift.

The Burnett Foundation has been a longtime benefactor to the Fort Worth community, enriching the citys arts, humanities, education, and health and human services.

This contribution bring the Lead On campaigns total funds raised to $671 million, putting it closer to the goal of $1 billion announced last October.

Read more: Lead On campaign to raise $1 billion

The campaign was initiated to strengthen the universitys endowment and its support of scholarships and academic programs, as well as to increase the diversity and inclusiveness of the student population.

With a goal of $1 billion, Lead On is the most ambitious campaign in the schools history.

View original post here:

$25 million donated to the TCU and UNTHSC School of Medicine - TCU 360

MADISON,WI(September 17, 2020) Robert Golden sees the danger of Alzheimers disease.

Among the 10 most deadly diseases [in America], he said, its the only one that cannot be prevented or cured at this time.

Golden is the dean of UWMadisons School of Medicine and Public Health, and he hosted a conversation about Alzheimers research during the Wisconsin Medicine Livestream event on September 15. Goldens guests included several of the UWs leading dementia researchers: Sanja Asthana, the founding director of the Wisconsin Alzheimers Disease Research Center; Sterling Johnson, the Finley Professor of Geriatrics and Dementia; Cynthia Carlsson, the Holland Professor of Alzheimers Disease; and Carey Gleason, a clinical neuropsychologist and member of the UW faculty.

Asthana noted that six million Americans suffer from Alzheimers and gave an overview of UW studies of the disease. He urged viewers to see the value of the universitys work. It is quite clear that the only way we can [beat] Alzheimers is through cutting-edge research, he said.

The key biomarker for Alzheimers is a buildup of amyloid proteins, and Johnson described efforts to increase doctors ability to recognize amyloid accumulations. Our goals are to identify Alzheimers before its symptoms appear, he said. You think of Alzheimers affecting the brain, and that means we have to get in and study the brain.

Carlsson added that amyloid isnt the only risk factor. Alzheimers also tends to show up more often in people who have high blood pressure, diabetes, poor sleep, traumatic brain injury, depression, and stress. The good news is these are things we can do something about, she said. She showed how a decrease in these other risk factors project to a 10 percent reduction of U.S. Alzheimers cases by 2050.

Gleason discussed recruitment for research projects, which have often drawn on an overrepresentation of white people, even though the prevalence of Alzheimers among Black and Native American populations is much higher. The UW has made a concerted effort to improve recruitment of underrepresented populations in its dementia studies, and the universitys success in this area is due to the way it has involved subjects as partners in the research process. We see them as true partners, she says, and not just bodies from which we collect data.

Golden brought forward questions from some of the hundreds of viewers who watched the event live on YouTube. To hear more from the members of the panel, view a recording of Wisconsin Medicine. The series is offered via YouTube and will continue into the fall. The next event will be September 29 and will cover the future of medicine.

See the rest here:

Wisconsin Medicine: Livestream on ending Alzheimers - Wisbusiness.com